肿瘤浸润淋巴细胞
过继免疫治疗
表型
祖细胞
免疫学
免疫疗法
癌症研究
生物
细胞疗法
癌症免疫疗法
过继性细胞移植
离体
癌症
细胞毒性T细胞
T细胞
干细胞
CD8型
免疫系统
体内
体外
细胞生物学
生物化学
生物技术
遗传学
基因
作者
Sri Krishna,Frank J. Lowery,Amy R. Copeland,Erol Bahadiroglu,Ratnadeep Mukherjee,Li Jia,James Anibal,Abraham Sachs,Serifat Adebola,Devikala Gurusamy,Zhiya Yu,Victoria Hill,Jared J. Gartner,Yong F. Li,Maria R. Parkhurst,Biman C. Paria,Pia Kvistborg,Michael C. Kelly,Stephanie L. Goff,Grégoire Altan‐Bonnet
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2020-12-10
卷期号:370 (6522): 1328-1334
被引量:536
标识
DOI:10.1126/science.abb9847
摘要
Stem-like T cells mediate response Adoptive cell transfer (ACT) is a type of immunotherapy that uses a patient's own T lymphocytes to recognize and attack cancer. ACT has been effective in treating certain patients with metastatic melanoma and is being applied to treat some epithelial cancers. Krishna et al. investigated why some cancer patients respond to ACT, whereas others do not. They identified a population of CD8 + T cells that had stem-like surface markers that were associated with effective tumor cell killing and favorable response of melanoma patients to ACT. Only a small subset of T cells specific against tumor mutations were found in this stem-like state, whereas most mutation-reactive T cells were terminally differentiated. These findings could be of value in improving cancer immunotherapy outcomes. Science , this issue p. 1328
科研通智能强力驱动
Strongly Powered by AbleSci AI